Collegium Pharmaceutical, Inc. Debt Securities, Available-for-sale, Amortized Cost
Collegium Pharmaceutical, Inc. (COLL) had Debt Securities, Available-for-sale, Amortized Cost of $157.51 million as of 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Notes › Debt Securities, Available-for-Sale, Amortized Cost
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-06
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $157.51M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $155.00M.
- 2024-12-31: Debt Securities, Available-for-sale, Amortized Cost $94.14M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-03-31 | $157.51M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $155.00M 10-Q · filed 2026-08-06 |
| 2024-12-31 | $94.14M 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |